{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:02:22Z","timestamp":1793084542585,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["520AUK701"],"award-info":[{"award-number":["520AUK701"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["520AUK701"],"award-info":[{"award-number":["520AUK701"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["520AUK701"],"award-info":[{"award-number":["520AUK701"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["520AUK701"],"award-info":[{"award-number":["520AUK701"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["520AUK701"],"award-info":[{"award-number":["520AUK701"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["520AUK701"],"award-info":[{"award-number":["520AUK701"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023448","name":"Robert Koch-Institut","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>People who inject drugs (PWID) are at high risk of blood-borne infections, and injection drug use contributes significantly to hepatitis C virus (HCV) transmission. The WHO has therefore set targets of reducing HCV incidence and prevalence among PWID and increasing treatment coverage to eliminate HCV by 2030. The DRUCK study (2011\u20132014) found high HCV prevalence and low treatment coverage among PWID in Germany. To assess progress in the elimination of HCV among PWID, we conducted a cross-sectional study in two German federal states that piloted a future monitoring.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PWID aged 16\u2009+\u2009who injected drugs (previous 12 months) were recruited in low-threshold drug services and opioid agonist treatment (OAT) practices in Berlin and Bavaria between June 2021 and April 2022. Participants completed a questionnaire on sociodemographics, behaviours and access to care, and were tested for hepatitis B\u00a0virus (HBV) and HCV, and HIV. Data was analysed regarding HCV prevalence, history of treatment, and risk and prevention behaviours. Results were compared with the DRUCK study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 588 PWID, with a median age of 39 (range: 17\u201366) years and 68% (399\/587) male, were included in the analysis. Of the participants, 61% (353\/574) reported receiving OAT and 14% (66\/469) recent use of shared\u00a0needles\/syringes during the last 30 days. History of imprisonment was reported by 77% (444\/577) and history of homelessness by 75% (428\/569) of participants. Among anti-HCV positive participants, viraemic HCV infections decreased by 44% from 66% (904\/1361) in 2011\u20132014 to 37% (160\/432) in 2021\u20132022, while those with cleared HCV infection and treatment history increased from 20% (266\/1361) to 34% (148\/432).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite a decrease since 2011\u20132014, viraemic HCV prevalence among PWID in Germany remains high, and treatment coverage is still insufficient. To achieve the WHO targets, universal health coverage and targeted integrated testing and treatment for PWID are needed. PWID receiving OAT and people in prison should be offered testing and treatment at any contact with the medical system. A nationwide monitoring system will help assess successes and remaining gaps, and track progress towards elimination of HCV among PWID in Germany.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01119-2","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:20:07Z","timestamp":1734693607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection"],"prefix":"10.1186","volume":"21","author":[{"given":"Gyde","family":"Steffen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrei","family":"Krings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Guttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Meyer-Schlinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Tiemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The DRUCK 2.0-study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Backmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Dorsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Ciomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gerlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Leicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kie\u00dfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Neumeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willehad","family":"Rensmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"St\u00f6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"1119_CR1","unstructured":"World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016 June 2016. Contract No.: WHO\/HIV\/2016.06."},{"key":"1119_CR2","unstructured":"United Nations General Assembly. Transforming our world: the 2030 Agenda for Sustainable Development General Assembly resolution A\/RES\/70\/1: United Nations General Assembly; 2015 [1\u201335]. Available from: https:\/\/www.un.org\/ga\/search\/view_doc.asp?symbol=A\/RES\/70\/1&Lang=E."},{"key":"1119_CR3","unstructured":"World Health Organization (WHO). Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. Geneva; 2022."},{"issue":"12","key":"1119_CR4","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"1119_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","volume":"4","author":"A Trickey","year":"2019","unstructured":"Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435\u201344.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1119_CR6","unstructured":"World Health Organization (WHO). Interim guidance for country validation of viral hepatitis elimination. Geneva; 2021."},{"key":"1119_CR7","unstructured":"European Union Drugs Agency (EUDA). Viral hepatitis elimination barometer among people who inject drugs in Europe Portugal: European Union Drugs Agency (EUDA); 2024 [updated July 2024. Available from: https:\/\/www.euda.europa.eu\/publications\/data-factsheet\/viral-hepatitis-elimination-barometer-among-people-who-inject-drugs-in-europe_en."},{"issue":"1","key":"1119_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2019","unstructured":"Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150\u201366.","journal-title":"Addiction"},{"key":"1119_CR9","doi-asserted-by":"crossref","unstructured":"Wiessing L, Kalamara E, Stone J, Altan P, Van Baelen L, Fotiou A, et al. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 - is the precautionary principle applicable? Euro Surveill. 2021;26(49).","DOI":"10.2807\/1560-7917.ES.2021.26.49.2002093"},{"issue":"2","key":"1119_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.drugpo.2012.08.006","volume":"24","author":"NE Palmateer","year":"2013","unstructured":"Palmateer NE, Hutchinson SJ, Innes H, Schnier C, Wu O, Goldberg DJ, et al. Review and meta-analysis of the association between self-reported sharing of needles\/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. Int J Drug Policy. 2013;24(2):85\u2013100.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1119_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/hex.13400","volume":"25","author":"M Paisi","year":"2022","unstructured":"Paisi M, Crombag N, Burns L, Bogaerts A, Withers L, Bates L, et al. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review. Health Expect. 2022;25(1):48\u201360.","journal-title":"Health Expect"},{"key":"1119_CR12","doi-asserted-by":"crossref","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):Cd012021.","DOI":"10.1002\/14651858.CD012021.pub2"},{"key":"1119_CR13","doi-asserted-by":"publisher","first-page":"103872","DOI":"10.1016\/j.drugpo.2022.103872","volume":"109","author":"N Palmateer","year":"2022","unstructured":"Palmateer N, Hamill V, Bergenstrom A, Bloomfield H, Gordon L, Stone J, et al. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). Int J Drug Policy. 2022;109:103872.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"1119_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.7326\/M21-3846","volume":"175","author":"JA Cepeda","year":"2022","unstructured":"Cepeda JA, Thomas DL, Astemborski J, Rudolph JE, Gicquelais R, Kirk GD, et al. Impact of hepatitis C treatment uptake on cirrhosis and mortality in persons who inject drugs\u202f: a longitudinal, community-based cohort study. Ann Intern Med. 2022;175(8):1083\u201391.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1119_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jhep.2018.09.030","volume":"70","author":"J Iversen","year":"2019","unstructured":"Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol. 2019;70(1):33\u20139.","journal-title":"J Hepatol"},{"issue":"12","key":"1119_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/jvh.13187","volume":"26","author":"A Trickey","year":"2019","unstructured":"Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, et al. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: a modelling study. J Viral Hepat. 2019;26(12):1388\u2013403.","journal-title":"J Viral Hepat"},{"key":"1119_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96: 103247.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1119_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250833","volume":"16","author":"P Buggisch","year":"2021","unstructured":"Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, G\u00f6rne H, et al. Barriers to initiation of hepatitis C virus therapy in Germany: a retrospective, case-controlled study. PLoS ONE. 2021;16(5): e0250833.","journal-title":"PLoS ONE"},{"key":"1119_CR19","unstructured":"HA-REACT - Joint Action on HIV and Co-infection Prevention and Harm Reduction. Report on PWID barriers to accessing HIV, HCV and TB services and on strategies for overcoming these barriers. HA-REACT; 2019."},{"key":"1119_CR20","unstructured":"World Health Organisation (WHO). Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organisation; 2022."},{"key":"1119_CR21","unstructured":"European Centre for Diasease Prevention (ECDC) and Control and European and The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Interageny guidance. Prevention and control of infectious diseases among people who inject drugs. Update 2023. Stockholm: European Centre for Diasease Prevention and Control (ECDC) and European and The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2023."},{"key":"1119_CR22","unstructured":"Bundesministerium f\u00fcr Gesundheit, Bundesministerium f\u00fcr wirtschaftliche Zusammenarbeit und Entwicklung. Strategie zur Eind\u00e4mmung von HIV, Hepatitis B und C und anderen sexuell \u00fcbertragbaren Infektionen. Bis 2030 - Bedarfsorientiert \u00b7 Integriert \u00b7 Sektor\u00fcbergreifend: Bundesministerium f\u00fcr Gesundheit; 2016 [Available from: http:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Praevention\/Broschueren\/Strategie_BIS_2030_HIV_HEP_STI.pdf."},{"issue":"36","key":"1119_CR23","first-page":"100792","volume":"13","author":"C Thomadakis","year":"2023","unstructured":"Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, et al. Prevalence of chronic HCV infection in EU\/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2023;13(36):100792.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"1119_CR24","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/S2214-109X(19)30462-0","volume":"8","author":"LA Hines","year":"2020","unstructured":"Hines LA, Trickey A, Leung J, Larney S, Peacock A, Degenhardt L, et al. Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. Lancet Glob Health. 2020;8(1):e76\u201391.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1119_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1186\/1471-2458-14-845","volume":"14","author":"R Zimmermann","year":"2014","unstructured":"Zimmermann R, Marcus U, Schaffer D, Leicht A, Wenz B, Nielsen S, et al. A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling. BMC Pub Health. 2014;14(1):845.","journal-title":"BMC Pub Health"},{"key":"1119_CR26","unstructured":"Robert Koch-Institut. Abschlussbericht der Studie \u201eDrogen und chronischen Infektionskrankheiten in Deutschland\u201c (DRUCK-Studie) Berlin: Robert Koch Institut; 2016 [updated 01.02.2016. Available from: http:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Studien\/DRUCK-Studie\/Abschlussbericht.pdf."},{"key":"1119_CR27","unstructured":"Gerlich M, Dichtl A, Graf N. Abschlussbericht zum Modellprojekt HIV? Hepatitis? Das CHECK ich! K\u00f6ln; 2020."},{"key":"1119_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7517-11-18","volume":"11","author":"H Stoever","year":"2014","unstructured":"Stoever H, Schaffer D. SMOKE IT! Promoting a change of opiate consumption pattern - from injecting to inhaling. Harm Reduct J. 2014;11:18.","journal-title":"Harm Reduct J"},{"key":"1119_CR29","unstructured":"World Health Organization (WHO). Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: World Health Organisation 2016 [Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/204790\/1\/9789241510288_eng.pdf."},{"issue":"1","key":"1119_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12954-024-00977-0","volume":"21","author":"A Krings","year":"2024","unstructured":"Krings A, Steffen G, Zimmermann R. Acceptance and feasibility of a low-threshold and substitution services-based periodical monitoring system for blood-borne and sexually transmitted infections among people who inject drugs in Germany: a mixed-methods analysis. Harm Reduct J. 2024;21(1):62.","journal-title":"Harm Reduct J"},{"key":"1119_CR31","unstructured":"Drug-related infectious diseases (DRID) toolkit: European Union Drugs Agency (EUDA); 2013 [Available from: https:\/\/www.euda.europa.eu\/publications\/manuals-and-guidelines\/drid-toolkit_en."},{"key":"1119_CR32","doi-asserted-by":"crossref","unstructured":"Gr\u00fcner N, Stambouli O, Ross RS. Dried blood spots--preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp. 2015(97).","DOI":"10.3791\/52619-v"},{"issue":"1","key":"1119_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0166-0934(94)90091-4","volume":"48","author":"S Viazov","year":"1994","unstructured":"Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, et al. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods. 1994;48(1):81\u201391.","journal-title":"J Virol Methods"},{"issue":"2","key":"1119_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jcv.2012.02.004","volume":"54","author":"S Bennett","year":"2012","unstructured":"Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, et al. Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol. 2012;54(2):106\u20139.","journal-title":"J Clin Virol"},{"key":"1119_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcv.2019.01.012","volume":"113","author":"A Walker","year":"2019","unstructured":"Walker A, Ennker KS, Kaiser R, L\u00fcbke N, Timm J. A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing. J Clin Virol. 2019;113:8\u201313.","journal-title":"J Clin Virol"},{"issue":"5\u20136","key":"1119_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","volume":"56","author":"C Poethko-M\u00fcller","year":"2013","unstructured":"Poethko-M\u00fcller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5\u20136):707\u201315.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"1119_CR37","unstructured":"UKHSA. Hepatitis C in England 2023: working to eliminate hepatitis C as a public health problem. Data to end of 2022. London; 2024."},{"issue":"3","key":"1119_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2021.09.038","volume":"76","author":"A Yeung","year":"2022","unstructured":"Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S, Barclay S, et al. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol. 2022;76(3):549\u201357.","journal-title":"J Hepatol"},{"issue":"10","key":"1119_CR39","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1128\/JCM.36.10.3070-3072.1998","volume":"36","author":"K Abe","year":"1998","unstructured":"Abe K, Konomi N. Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. J Clin Microbiol. 1998;36(10):3070\u20132.","journal-title":"J Clin Microbiol"},{"key":"1119_CR40","doi-asserted-by":"crossref","unstructured":"Schroter M, Zollner B, Laufs R, Feucht HH. Changes in the prevalence of hepatitis C virus genotype among injection drug users: a highly dynamic process. J Infect Dis. 2004;190(6):1199\u2013200; author reply 200\u20131.","DOI":"10.1086\/423622"},{"key":"1119_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcv.2016.05.010","volume":"81","author":"V Kartashev","year":"2016","unstructured":"Kartashev V, D\u00f6ring M, Nieto L, Coletta E, Kaiser R, Sierra S. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J Clin Virol. 2016;81:82\u20139.","journal-title":"J Clin Virol"},{"issue":"1","key":"1119_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2017.01.024","volume":"67","author":"R Zimmermann","year":"2017","unstructured":"Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. Real-world treatment for chronic hepatitis C infection in Germany: analyses from drug prescription data, 2010\u20132015. J Hepatol. 2017;67(1):15\u201322.","journal-title":"J Hepatol"},{"key":"1119_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/a-1824-7646","volume":"23","author":"B Schulte","year":"2022","unstructured":"Schulte B, Jacobsen B, Kuban M, Kraus L, Reimer J, Schmidt CS, et al. Umsetzung von Testung, Diagnostik und Behandlung der hepatitis C in Einrichtungen der niedrigschwelligen Drogenhilfe in Deutschland \u2013 eine Querschnittsbefragung. Suchttherapie (EFirst). 2022;23:121\u20139.","journal-title":"Suchttherapie (EFirst)"},{"key":"1119_CR44","unstructured":"European Union Drugs Agency (EUDA). European Drug Report 2024: Trends and Developments: European Union Drugs Agency (EUDA); 2024. Available from: https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2024_en."},{"issue":"1","key":"1119_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12954-023-00870-2","volume":"20","author":"F Hommes","year":"2023","unstructured":"Hommes F, Krings A, D\u00f6rre A, Neumeier E, Sch\u00e4ffer D, Zimmermann R. International harm reduction indicators are still not reached: results from a repeated cross-sectional study on drug paraphernalia distribution in Germany, 2021. Harm Reduct J. 2023;20(1):137.","journal-title":"Harm Reduct J"},{"issue":"12","key":"1119_CR46","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1473-3099(18)30469-9","volume":"18","author":"J Stone","year":"2018","unstructured":"Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397\u2013409.","journal-title":"Lancet Infect Dis"},{"key":"1119_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugpo.2017.12.013","volume":"54","author":"EB Cunningham","year":"2018","unstructured":"Cunningham EB, Hajarizadeh B, Amin J, Bretana N, Dore GJ, Degenhardt L, et al. Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: the HITS-p study. Int J Drug Policy. 2018;54:18\u201325.","journal-title":"Int J Drug Policy"},{"key":"1119_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijid.2019.01.015","volume":"81","author":"M Gassowski","year":"2019","unstructured":"Gassowski M, Nielsen S, Bannert N, Bock CT, Bremer V, Ross RS, et al. History of detention and the risk of hepatitis C among people who inject drugs in Germany. Int J Infect Dis. 2019;81:100\u20136.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"1119_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00103-023-03808-y","volume":"67","author":"A Dichtl","year":"2024","unstructured":"Dichtl A, Jamin D, St\u00f6ver H, Grabski M, Knorr B. Hepatitis C in prisons\u202f: treatment and barriers to the elimination goals of the United Nations. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024;67(1):36\u201344.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"1119_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12954-019-0340-4","volume":"16","author":"H St\u00f6ver","year":"2019","unstructured":"St\u00f6ver H, Jamin D, Michels II, Knorr B, Keppler K, Deimel D. Opioid substitution therapy for people living in German prisons-inequality compared with civic sector. Harm Reduct J. 2019;16(1):72.","journal-title":"Harm Reduct J"},{"key":"1119_CR51","unstructured":"BAG Wohnungslosenhilfe e.V. Mindestens 607.000 Menschen in Deutschland wohnungslos Berlin: BAG Wohnungslosenhilfe e.V.; 2023 [Available from: https:\/\/www.bagw.de\/de\/themen\/zahl-der-wohnungslosen\/uebersicht."},{"key":"1119_CR52","first-page":"8","volume":"13","author":"G Steffen","year":"2022","unstructured":"Steffen G, Weber C, Cawley C, Sarma N, Jansen K, Leicht A, et al. Pr\u00e4valenz von sexuell und durch Blut \u00fcbertragbaren Infektionen und Tuberkulose bei Menschen in Wohnungslosigkeit in Berlin \u2013 Erste Ergebnisse der Pilotstudie POINT. Epidemiologisches Bull. 2022;13:8.","journal-title":"Epidemiologisches Bull"},{"issue":"2","key":"1119_CR53","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2468-2667(21)00258-9","volume":"7","author":"J Stone","year":"2022","unstructured":"Stone J, Artenie A, Hickman M, Martin NK, Degenhardt L, Fraser H, et al. The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. Lancet Pub Health. 2022;7(2):e136\u201345.","journal-title":"Lancet Pub Health"},{"key":"1119_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-016-3545-4","volume":"16","author":"B Wenz","year":"2016","unstructured":"Wenz B, Nielsen S, Gassowski M, Santos-H\u00f6vener C, Cai W, Ross RS, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011\u201314). BMC Pub Health. 2016;16:1\u201314.","journal-title":"BMC Pub Health"},{"issue":"3","key":"1119_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/diagnostics11030473","volume":"11","author":"F Vel\u00e1squez-Orozco","year":"2021","unstructured":"Vel\u00e1squez-Orozco F, Rando-Segura A, Mart\u00ednez-Camprecios J, Salmeron P, Najarro-Centeno A, Esteban \u00c0, et al. Utility of the Cobas(\u00ae) plasma separation card as a sample collection device for serological and virological diagnosis of hepatitis C virus infection. Diagnostics (Basel). 2021;11(3):473.","journal-title":"Diagnostics (Basel)"},{"key":"1119_CR56","first-page":"3","volume":"42","author":"ASG Krings","year":"2020","unstructured":"Krings ASG, Germershausen C, Zimmermann R. Auswirkungen der COVID-19-Krise auf Pr\u00e4ventionsangebote zu durch Blut und sexuell \u00fcbertragenen Infektionen bei Drogengebrauchenden. EpidBull. 2020;42:3\u20139.","journal-title":"EpidBull"},{"key":"1119_CR57","unstructured":"World Health Organization (WHO), United Nations Office on Drugs and Crime. International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing. Geneva; 2020 March 31."},{"key":"1119_CR58","unstructured":"European Centre for Disease Prevention and Control (ECDC), European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prevention and control of infectious diseases among people who inject drugs \u2014 2023 update. Stockholm, Sweden; 2023 07.11.2023."},{"key":"1119_CR59","unstructured":"World Health Organization (WHO). New recommendation on hepatitis C virus testing and treatment for people at ongoing risk of infection. World Health Organization (WHO); 2023."},{"issue":"Suppl 5","key":"1119_CR60","doi-asserted-by":"publisher","first-page":"v17","DOI":"10.1093\/jac\/dkz452","volume":"74","author":"J Surey","year":"2019","unstructured":"Surey J, Menezes D, Francis M, Gibbons J, Sultan B, Miah A, et al. From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J Antimicrob Chemother. 2019;74(Suppl 5):v17\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"1119_CR61","unstructured":"Condrobs e.V. Sachbericht 2022. Health Advisor Projekt M\u00fcnchen. M\u00fcnchen: condrobs e.V.; 2023."},{"issue":"1","key":"1119_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12954-023-00743-8","volume":"20","author":"M Di Ciaccio","year":"2023","unstructured":"Di Ciaccio M, Villes V, Perfect C, El Kaim JL, Donatelli M, James C, et al. Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey. Harm Reduct J. 2023;20(1):15.","journal-title":"Harm Reduct J"},{"key":"1119_CR63","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hepatitis C: new models of care for drugs services. Luxembourg; 2019."},{"key":"1119_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102489","volume":"69","author":"MJ Hayes","year":"2024","unstructured":"Hayes MJ, Beavon E, Traeger MW, Dillon JF, Radley A, Nielsen S, et al. Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis. EClinicalMedicine. 2024;69: 102489.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"1119_CR65","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/liv.15266","volume":"42","author":"H Midgard","year":"2022","unstructured":"Midgard H, Bj\u00f8rnestad R, Egeland M, Dahl E, Finbr\u00e5ten AK, Kielland KB, et al. Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. Liver Int. 2022;42(6):1268\u201377.","journal-title":"Liver Int"},{"issue":"10","key":"1119_CR66","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1111\/add.15459","volume":"116","author":"NE Palmateer","year":"2021","unstructured":"Palmateer NE, McAuley A, Dillon JF, McDonald S, Yeung A, Smith S, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction. 2021;116(10):2893\u2013907.","journal-title":"Addiction"},{"issue":"11","key":"1119_CR67","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.drugpo.2015.04.015","volume":"26","author":"DC Perlman","year":"2015","unstructured":"Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, et al. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015;26(11):1056\u201363.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1119_CR68","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S2468-1253(20)30365-4","volume":"6","author":"MJ Akiyama","year":"2021","unstructured":"Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, et al. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol. 2021;6(5):391\u2013400.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1119_CR69","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jhep.2023.04.019","volume":"79","author":"Y Sheehan","year":"2023","unstructured":"Sheehan Y, Cunningham EB, Cochrane A, Byrne M, Brown T, McGrath C, et al. A \u201cone-stop-shop\u201d point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study. J Hepatol. 2023;79(3):635\u201344.","journal-title":"J Hepatol"},{"issue":"1","key":"1119_CR70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jvh.13017","volume":"26","author":"S Morey","year":"2019","unstructured":"Morey S, Hamoodi A, Jones D, Young T, Thompson C, Dhuny J, et al. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. J Viral Hepat. 2019;26(1):101\u20138.","journal-title":"J Viral Hepat"},{"key":"1119_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108717","volume":"224","author":"MF McLaughlin","year":"2021","unstructured":"McLaughlin MF, Li R, Carrero ND, Bain PA, Chatterjee A. Opioid use disorder treatment for people experiencing homelessness: a scoping review. Drug Alcohol Depend. 2021;224: 108717.","journal-title":"Drug Alcohol Depend"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01119-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:04:17Z","timestamp":1734696257000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01119-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01119-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the DRUCK 2.0 study, including the evaluation, was provided by the Medical Chamber Berlin (ETH-51\/10). All participants signed a written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DRUCK 2.0 study group: Condrobs e.V., employer of Olaf Ostermann, cooperates with Abbvie and Gilead. No conflict of interest declared by the other study group members.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}